References
- Kobayashi M, Iwanishi M, Egawa K, Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992;41:476–83
- Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARg). J Biol Chem 1995;270:12953–6
- Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83:803–12
- Auwex J. PPAR-γ, the ultimate thrifty gene. Diabetologia 1999;42:1033–49
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–32
- Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993;259:87–91
- Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 1998;41:257–64
- Odaka H, Shino A, Ikeda H, Matuso T. Antiobesity and antidiabetic actions of a new potent disaccharidase inhibitor in genetically obese-diabetic mice, KKAy. J Nutr Sci Vitaminol 1992;3827–37
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502
- Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Scheneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605–11
- Lacivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363–70
- Baba S. Pioglitazone: a review of Japanese clinical studies. Curr Med Res Opin 2001;17:166–89
- Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999;401:73–6
- Okuno A, Tamemoto H, Tobe K, Kadowaki T. Effects of thiazolidinediones on adipose tissue as a target organ to ameliorate insulin resistance. Saishin Igaku 1997;52:1153–60
- Takahashi M, Funahashi T, Shimomura I, Miyaoka K, Matsuzawa Y. Plasma leptin levels and body fat distribution. Horm Metab Res 1996;28:751–2
- Kelly IE, Walsh K, Han TS, Lean MEJ. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288–93
- Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22:908–12
- Liu J, Askari H, Dagogo-Jack S. Basal and stimulated plasma leptin in diabetic subjects. Obes Res 1999;7:537–44
- Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelmam BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996;271:665–8
- Hayakawa T, Shiraki T, Morimoto T, Shii K, Ikeda H. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Commun 1996;223: 439–44
- Chen C. Troglitazone: an antidiabetic agent. Am J Health-Syst Pharm 1998;55:905–25
- Balfour JAB, Plosker GL. Rosiglitazone. Drug 1999;57:921–30
- Krische D. The glitazones: proceed with caution. West J Med 2000;173:54–7
- Evans DJ, Hoffmann GR, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 1984;33:68–76
- Suter SL, Nlan JJ, Wallace P, Gumbiner B, Olfsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15: 193–203
- Yamasaki Y, Kawamori R, Wasada T, et al. Pioglitazone (AD-4833) Ameliorates insulin resistance in patients with NIDDM. Tohoku J Exp Med 1997;183:173–83